Attribution of Value between Combination Therapies: Illustration, Discussion & Case-Studies
Discussion Leaders: Andrew Briggs, DPhil, Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK John Schneider, PhD, Avalon Health Economics, Morristown, NJ, USA;Eric William Low, NA, Eric Low Consulting, Haddington, ELN, UK; Tanja Podkonjak, MBA, Takeda UK Ltd, London, LON, UK
DESCRIPTION: We will present a proposed value attribution framework that can be used to address the problem of pricing combination products fairly to manufacturers of the component products AND payers within the health system. We present solutions to four scenarios of combination therapies that are characterized by key features of the problem: perfect/imperfect information about the monotherapy effect of component therapies (individual effects are known/unknown) and balanced/unbalanced market power between their manufacturers (unbalanced being where one manufacturer already has market access and a new entrant seeks to add to this 'backbone' therapy) . Case studies are used to illustrate each scenario drawn from publicly available information of recent combination therapy submissions to NICE. Consideration will be given to the process of negotiation that can help navigate anti-trust rules designed to prevent price collusion.
Conference/Value in Health Info
Health Policy & Regulatory